Innovative Biomaterials Humabiologics specializes in high-quality, human-derived biomaterials such as gelatin, collagen, and extracellular matrices, providing researchers with ethically sourced, regulatory-friendly materials that can accelerate translational research and therapeutic development.

Strategic Collaborations The company has established partnerships with RegenMed Engine, Wake Forest Institute for Regenerative Medicine, and Allegro 3D, positioning it as a key player in the development of bioprinting, tissue models, and regenerative therapies—opportunities for vendors and collaborators in medtech and biomanufacturing.

Recent Funding & Recognition With a revenue between 1 million and 10 million dollars and recent awards like the AZBio Fast Lane Award, Humabiologics demonstrates growth potential and industry recognition, making it an appealing partner for sourcing innovative biomaterials or investing in regenerative research projects.

Expanding Tech Capabilities Humabiologics is engaged in developing tissue models for drug screening, regenerative medicine, and 3D bioprinting, indicating a strong focus on cutting-edge biosciences and necessitating advanced bioprinting equipment, custom biomaterial formulations, and related technological solutions.

Market Positioning Operating within the niche of human tissue biomaterials and regenerative research, Humabiologics is well-positioned to serve biotech firms, research institutions, and medical device companies seeking innovative materials and collaborative development opportunities for next-generation therapeutics.